FDA NDC Directory · JSON-LD · Markdown

Arcalyst

NDC 73604-914 · HUMAN PRESCRIPTION DRUG · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Generic namerilonacept
Labeler / ManufacturerKiniksa Pharmaceuticals (UK), Ltd.
Marketing categoryBiologic License Application · App BLA125249
Dosage form / routeINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · SUBCUTANEOUS
Active ingredientsRILONACEPT (160 mg/2mL)
Marketing started20080227
Package count2

External sources

Source: openFDA. Public-domain (CC0).